Marwan ElBagoury

Marwan ElBagoury

Auto-generated profile, based on publicly available information

Marwan ElBagoury

Universität Ulm - Medizinische Fakultät, Ulm, Deutschland

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2021 in Journal of Infection and Public Health
Verified
Journal Article
Open access
MEMarwan ElBagoury
Marwan ElBagoury
MTMahmoud Tolba
Mahmoud Tolba
HNHebatallah A. Nasser
Hebatallah A. Nasser
AJAbdul Jabbar
Abdul Jabbar
AEAhmed M. Elagouz
Ahmed M. Elagouz
AHAmy Hutchinson
Amy Hutchinson
Severe acute respiratory syndrome coronavirus (SARS-CoV-2), a novel corona virus, causing COVID-19 with Flu-like symptoms is the first alarming pandemic of the third millennium. SARS-CoV-2 belongs to beta coronavirus as Middle East respiratory syndrome coronavirus (MERS-CoV). Pandemic COVID-19 owes devastating mortality and destructively exceptional consequences on Socio-Economics life around the world. Therefore, the current review is redirected to the scientific community to owe comprehensive visualization about SARS-CoV-2 to tackle the current pandemic. As systematically shown through the current review, it indexes unmet medical problem of COVID-19 in view of public health and vaccination discovery for the infectious SARS-CoV-2; it is currently under-investigational therapeutic protocols, and next possible vaccines. Furthermore, the review extensively reports the precautionary measures to achieve" COVID-19/Flatten the curve". It is concluded that vaccines formulation within exceptional no time in this pandemic is highly recommended, via following the same protocols of previous pandemics; MERS-CoV and SARS-CoV, and excluding some initial steps of vaccination development process.

30 March 2018 in Journal of Pure and Applied Microbiology
Verified
Journal Article
Open access
MKMaryam Kotb
Maryam Kotb
MEMarwan ElBagoury
Marwan ElBagoury

30 March 2018 in Journal of Pure and Applied Microbiology
Verified
Journal Article
Open access
KHKarim Hassan
Karim Hassan
MEMarwan ElBagoury
Marwan ElBagoury

30 December 2017 in Journal of Pure and Applied Microbiology
Verified
Journal Article
Open access
KHKarim Hassan
Karim Hassan
MEMarwan El-Bagoury
Marwan El-Bagoury

22 February 2019 in International Journal Of Community Medicine And Public Health
Verified
Journal Article
Open access
PDF file
NSNagham Sheblaq
Nagham Sheblaq
ZAZainab Albahooth
Zainab Albahooth
FAFatmah Alfawzan
Fatmah Alfawzan
KAKhalid Alanazi
Khalid Alanazi
SASawsan Alshouli
Sawsan Alshouli
ANAmal Najjar
Amal Najjar
Background: Screening approved medications to identify therapeutics for drug repurposing is an effective tactic, and a deep research into off label drug use (OLDU) is required. Unfortunately, OLDU has not been extensively studied in Middle East. Our study aimed to evaluate the extent of OLDU in Saudi Arabia.Methods: Retrospective study carried out during 12 month period at six tertiary hospitals in Saudi Arabia. Each prescription was evaluated as unlicensed or OLDU based on the product information or based on Food and drug Administration (FDA) approval.Results: A total of 288 prescriptions were analyzed, where the reasons for off-label prescribing were OLDU by indication (94.42%), OLDU by different age group (2.09%), and other reasons represented (3.48%). Adults/geriatrics (≥18 years) received (89.05%) of the orders, and children (1-11 years) received (7.78%) of the orders. Both adolescents (12-18 years) and neonates (1-29 days) received (1.42%) of the orders per each category, while infants (1 month-1 year) received (0.36%) of the orders. The therapeutic classes most often prescribed were antidepressants (21.88%), antidiabetics (17.71%), and atypical antipsychotics (10.06%).Conclusions: Off-label prescribing was found in most adults/geriatrics suffering from depression, and diabetes mellitus. The most common reason for off-label prescription was off-label by indication. The results call for the need to conduct more studies with larger sample size, do more investigations on the OLDU in the whole kingdom, and develop policy for OLDU across hospitals.

31 August 2021 in JMIR Research Protocols
Verified
Journal Article
Open access
DADanyah Alsafadi
Danyah Alsafadi
AEAly Ezzat
Aly Ezzat
FAFatima Altamimi
Fatima Altamimi
MEMarwan ElBagoury
Marwan ElBagoury
MOMohammed Olfat
Mohammed Olfat
YAYahia Aktham
Yahia Aktham
Background: Since the underlying cause of idiopathic short stature can indeed be undiagnosed mucopolysaccharidosis type I, it is critical to identify patients with mucopolysaccharidosis type I among screened patients with idiopathic short stature. Objective: The primary objective of this study is to determine the prevalence of mucopolysaccharidosis type I disease in a high-risk group (ie, patients with idiopathic short stature). Methods: We plan to perform a multicenter, cross-sectional screening study to primarily assess the prevalence of mucopolysaccharidosis type I disease in patients with idiopathic short stature. All eligible patients will be tested after obtaining written informed consent from their parents and guardians. Eligible patients will be recruited over 18 months from specialty care centers for pediatrics and genetics. Results: This protocol was approved by the Institutional Review Board of King Fahd Medical City and funded by Sanofi Genzyme Saudi Arabia. We expect to collect data from ≥800 patients, as determined by our sample size calculation. Conclusions: Saudi Arabia is the largest country in the Arabian Peninsula; it has a population of more than 28 million people. To date, there are no reliable data regarding the incidence and prevalence of mucopolysaccharidosis type I in Saudi Arabia; therefore, future multicenter studies will be needed. Further, the prevalence of an attenuated form of mucopolysaccharidosis type I is largely underestimated in Saudi Arabia due to the absence of an effective newborn screening program. Therefore, the implementation of a nationwide newborn screening program is essential for the accurate estimation of the burden of mucopolysaccharidosis and the early diagnosis of patients. International Registered Report Identifier (IRRID): PRR1-10.2196/28619